5 Pain Therapeutics Analyst Ratings, Earnings, Dividends and Insider Trades | $PTIE | NASDAQ:PTIE | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Pain Therapeutics Company Profile (NASDAQ:PTIE) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Pain Therapeutics (NASDAQ:PTIE) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s)Consensus Rating:Hold (Score: 2.00)Consensus Price Target: $5.10 6.08% downside) Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare12/24/2013ZacksDowngradeOutperform -> Neutral$5.10View 10/28/2013ZacksUpgradeNeutral -> Outperform$4.10View 5/8/2013GabelliDowngradeBuy -> HoldView 11/1/2012C.K. CooperDowngradeBuy -> HoldView 8/17/2012C.K. CooperInitiated CoverageBuy$12.00View (Data available from 3/8/2012 forward) Earnings History for Pain Therapeutics (NASDAQ:PTIE)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/4/2014Q413($0.01)$0.72$2.00 million$35.24 millionViewN/AView 10/31/2013Q313($0.01)($0.02)$2.00 million$1.96 millionViewN/AView 4/24/2013Q1 2013($0.01)($0.01)$2.80 million$1.96 millionViewN/AView 2/6/2013Q4 2012($0.02)($0.08)$2.79 million$2.47 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Pain Therapeutics (NASDAQ:PTIE)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare12/11/2012special$0.7512/13/201212/17/201212/24/2012 (Data available from 1/1/2013 forward) Insider Trading History for Pain Therapeutics (NASDAQ:PTIE)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare11/6/2013Sanford RobertsonDirectorBuy50,000$3.73$186,500.00View (Data available from 1/1/2013 forward) About Pain Therapeutics Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, it leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo. Headlines: (3/6) Pain Therapeutics Invited to Present at 26th Annual ROTH Conference (2/25) Pain Therapeutics Invited to Present at Cowen Health Care Conference in Boston (3/3) Pain Therapeutics (PTIE) Enters Overbought Territory (3/3) Pain Therapeutics (PTIE) Enters Overbought Territory - Tale of the Tape (3/3) Pain Therapeutics To Present At The Cowen And Co. Conference; Webcast At 3:30PM Industry, Sector and Symbol: Sector: Healthcare Industry: Pharmaceuticals Sub-Industry: Pharmaceuticals Exchange: NASDAQ Symbol: PTIE CUSIP: 69562K10 Key Metrics: Previous Close: $5.5050 Day Moving Average: $4.8747200 Day Moving Average: $3.9054 P/E Ratio: 7.86P/E Growth: N/AMarket Cap: $247.1MCurrent Quarter EPS Consensus Estimate: $-0.28 EPS Additional Links: View PTIE on Google FinanceView PTIE on Yahoo FinanceView PTIE's Company Profile on ReutersSearch for Pain Therapeutics Inc. on Google Pain Therapeutics (NASDAQ:PTIE) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.